NASDAQ:SNSS - Sunesis Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.55 +0.01 (+1.85 %)
(As of 02/21/2019 04:20 AM ET)
Previous Close$0.54
Today's Range$0.53 - $0.55
52-Week Range$0.20 - $7.69
Volume275,700 shs
Average Volume764,282 shs
Market Capitalization$20.58 million
P/E Ratio-0.38
Dividend YieldN/A
Beta2.69
Sunesis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company also engages in developing TAK-580, a pan-Raf inhibitor program in combination with various anticancer agents for the treatment of advanced solid tumor cancers in adult patients; SNS-510, which is in preclinical pharmacology and toxicology studies for the treatment of solid tumor and hematologic malignancies; and vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). In addition, it is developing vosaroxin, which is in Phase 2 trial with decitabine for treatment of diagnosed acute AML or myelodysplastic syndrome (MDS); Phase 1/2 trial with azacitidine for treatment of MDS; Phase 2 trial with infusional cytarabine for treatment of AML; Phase 1/2 trial in adult patients with previously treated intermediate-2 or high-risk MDS; and Phase 1/2 trial with cytarabine tested as consolidation therapy. The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Receive SNSS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SNSS
CUSIP86732860
Phone650-266-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$670,000.00
Book Value$0.02 per share

Profitability

Net Income$-35,450,000.00

Miscellaneous

Employees34
Market Cap$20.58 million
OptionableOptionable

Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.24) by $0.04. View Sunesis Pharmaceuticals' Earnings History.

When is Sunesis Pharmaceuticals' next earnings date?

Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Sunesis Pharmaceuticals.

What price target have analysts set for SNSS?

3 brokers have issued 1-year target prices for Sunesis Pharmaceuticals' stock. Their predictions range from $0.50 to $4.00. On average, they anticipate Sunesis Pharmaceuticals' share price to reach $2.25 in the next year. This suggests a possible upside of 309.1% from the stock's current price. View Analyst Price Targets for Sunesis Pharmaceuticals.

What is the consensus analysts' recommendation for Sunesis Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sunesis Pharmaceuticals.

Has Sunesis Pharmaceuticals been receiving favorable news coverage?

Headlines about SNSS stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Sunesis Pharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days.

Who are some of Sunesis Pharmaceuticals' key competitors?

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the folowing people:
  • Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)
  • Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)
  • Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)
  • Mr. Gene C. Jamieson, VP of Technical Operations
  • Dr. Judith A. Fox, Chief Scientific Officer

Who are Sunesis Pharmaceuticals' major shareholders?

Sunesis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Aisling Capital Management LP (6.95%), Rhenman & Partners Asset Management AB (1.01%) and Great Point Partners LLC (0.85%). Company insiders that own Sunesis Pharmaceuticals stock include Dayton Misfeldt, Mpm Oncology Impact Management and William P Quinn. View Institutional Ownership Trends for Sunesis Pharmaceuticals.

Which institutional investors are selling Sunesis Pharmaceuticals stock?

SNSS stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC and Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Sunesis Pharmaceuticals.

Which institutional investors are buying Sunesis Pharmaceuticals stock?

SNSS stock was purchased by a variety of institutional investors in the last quarter, including Aisling Capital Management LP. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Dayton Misfeldt, Mpm Oncology Impact Management and William P Quinn. View Insider Buying and Selling for Sunesis Pharmaceuticals.

How do I buy shares of Sunesis Pharmaceuticals?

Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of SNSS stock can currently be purchased for approximately $0.55.

How big of a company is Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals has a market capitalization of $20.58 million and generates $670,000.00 in revenue each year. The biopharmaceutical company earns $-35,450,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Sunesis Pharmaceuticals employs 34 workers across the globe.

What is Sunesis Pharmaceuticals' official website?

The official website for Sunesis Pharmaceuticals is http://www.sunesis.com.

How can I contact Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]


MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  338 (Vote Underperform)
Total Votes:  664
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel